CAR-T Cells for Liver Cancer After Surgery
Part of Cancer clinical trials.
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have stage IIIa liver cancer (HCC) that has spread into a blood vessel in the liver (like the portal or hepatic vein).
- You had surgery to remove the tumor, and your AFP level (a tumor marker) is now going up, suggesting the cancer might come back.
- Your tumor cells have a protein called GPC3 on them (this will be checked in a lab).
- You are healthy enough to undergo a procedure to collect your blood cells (called apheresis) and have stable liver and kidney function.
- You have not had any previous cell therapy (like CAR-T cells) and do not have other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
This trial tests a new treatment called CAR-T cells that are designed to find and attack liver cancer cells with a specific marker (GPC3). If you have advanced hepatocellular carcinoma (liver cancer) that has not responded to standard treatments, this study may be an option to explore.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial tests a new treatment called CNCT19, which uses your own immune cells to fight liver cancer. It's for people with advanced liver cancer that hasn't responded to standard treatments or can't be treated with surgery or local procedures.
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.